Novo Nordisk Adr (NVO)

Feb 13, 2026

Novo Nordisk Faces Legal And FDA Challenges As Valuation Gap Widens - Sahm

Feb 13, 2026

Feb 13, 2026

Meet the 6.3% Yield Dividend Stock That Could Soar in 2026 - The Motley Fool

Feb 13, 2026

Feb 10, 2026

Where is Novo Nordisk A/S (NVO) Headed? - Finviz

Feb 10, 2026

Feb 09, 2026

Novo Nordisk Lawsuit Tests Obesity Drug Patents And Valuation Upside - Sahm

Feb 09, 2026

Feb 08, 2026

Novo Nordisk A/S (NVO) Eyes Solidifying Its Market Position with Increased Advertising Spending - Finviz

Feb 08, 2026

Feb 07, 2026

Jim Cramer on Novo Nordisk: "It Seems Eli Lilly's Eating Their Lunch" - Finviz

Feb 07, 2026

Feb 06, 2026

Novo Nordisk Warning Tests Valuation As Pricing And Competition Intensify - Sahm

Feb 06, 2026

Feb 05, 2026

Ozempic Maker Novo Nordisk Flags Declining Sales In 2026 - Sahm

Feb 05, 2026

Feb 04, 2026

Novo Nordisk Faces a Sales Decline in 2026, But Its Portfolio and Pipeline Provide Long-Term Growth - Morningstar

Feb 04, 2026

Feb 04, 2026

Novo Nordisk Plunges After Releasing a Brutal Forecast. Should You Dump the Stock? - Finviz

Feb 04, 2026

Feb 04, 2026

NVO Q4 Earnings & Sales Beat Estimates, Stock Down on Poor 2026 View - Finviz

Feb 04, 2026

Feb 04, 2026

Novo Nordisk ADR earnings beat by $0.10, revenue topped estimates - Investing.com South Africa

Feb 04, 2026

Feb 03, 2026

Novo Nordisk's U.S. listing drops significantly after earnings report - medwatch.com

Feb 03, 2026

Feb 02, 2026

Novo Nordisk A/S (NVO): A Bull Case Theory - Finviz

Feb 02, 2026

Feb 02, 2026

Jim Cramer Believes Novo Nordisk "Is a Hold, Not a Buy" - Finviz

Feb 02, 2026

Feb 02, 2026

Is Novo Nordisk Stock a Bargain Right Now? - Finviz

Feb 02, 2026

Jan 31, 2026

BMO Raises Novo Nordisk A/S (NVO) Price Target but Flags Prescription Pressures - Finviz

Jan 31, 2026

Jan 31, 2026

Should You Buy Novo Nordisk Stock on Oral Wegovy's Strong Launch? - Finviz

Jan 31, 2026

Jan 31, 2026

Novo Nordisk Oral Wegovy Launch Reshapes Obesity Access And Valuation Outlook - Sahm

Jan 31, 2026

Jan 30, 2026

Demand for Novo Nordisk's Weight Loss Pill Is Strong Out of the Gate. Is the Stock Due for a Big Rally? - Finviz

Jan 30, 2026

Jan 30, 2026

Novo Nordisk Before Q4 Earnings: How Should Investors Play the Stock? - Finviz

Jan 30, 2026

Jan 25, 2026

5 Stocks To Keep an Eye On in 2026, According to Experts - AOL.com

Jan 25, 2026

Jan 24, 2026

Novo Nordisk’s Wegovy Pill And Akero Deal Reframe Obesity Growth Story - Sahm

Jan 24, 2026